Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis

Kazutoshi Sugiyama, Shu Meguro*, Yoshifumi Saisho, Junichiro Irie, Masami Tanaka, Hiroshi Itoh. Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis. Heliyon 5 (2019) e01257. doi: 10.1016/j.heliyon.2019.e01257

Abstract

Aims: To evaluate the efficacy and safety of switching to insulin glargine 300 U/mL (Gla-300) from insulin glargine 100 U/mL (Gla-100) in Japanese patients with type 2 diabetes (T2DM).

Methods: This was a 12-month retrospective study comprising 109 patients. Primary endpoint was glycated hemoglobin (HbA1c) level at month 12. Secondary endpoints were hypoglycemia for the overall study period as well as body weight and insulin dose at month 12.

Results: Similar glycemic control was achieved with mean (standard deviation) HbA1c level of 7.7 (1.1)% (61 [12] mmol/mol) at baseline and 7.7 (1.3)% (61 [14] mmol/mol) at month 12. Fewer confirmed (<3.0 mmol/L [< 54 mg/dL]) or severe hypoglycemic events were observed (0.52 vs. 0.85 events per patient-year; rate ratio 0.61; 95% confidence interval 0.38—0.97; p = 0.037), but the percent of patients experiencing ≥1 hypoglycemic event did not differ. There
was no difference in confirmed (≤3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemia.

Conclusions: In Japanese patients with T2DM who switched to Gla-300 from Gla-100, similar glycemic control was achieved with fewer confirmed (<3.0 mmol/L [< 54 mg/dL]) or severe hypoglycemic events over a 12-month period, although the absolute benefit was marginal.

Keywords: Metabolism, Evidence-based medicine

1. Introduction

The importance of achieving a good glycemic control in order to prevent microvascular diseases in patients with type 2 diabetes (T2DM) has been well documented [1, 2, 3]. Although it can be initially achieved with lifestyle modifications and oral antihyperglycemic drugs, many patients with T2DM eventually require and benefit from insulin therapy due to its progressive nature [4]. However, insulin therapy is associated with more frequent hypoglycemia, exposing patients to an array of autonomic and neuroglycopenic symptoms [5]. Consequently, hypoglycemia is associated with a lower health-related quality of life [6] and is the major limiting factor in the glycemic management of diabetes [7].

Recently, insulin glargine 300 U/mL (Gla-300) was approved for the treatment of diabetes. It has a more constant and prolonged pharmacokinetic (PK) and pharmacodynamic (PD) profile than those of insulin glargine 100 U/mL (Gla-100) and has been expected to confer a lower hypoglycemic risk [8, 9]. The efficacy and safety of Gla-300 vs. Gla-100 were investigated in the EDITION program of randomized phase III studies, and patients treated with Gla-300 experienced fewer nocturnal hypoglycemia while achieving a similar glycemic control [10, 11, 12, 13, 14, 15, 16, 17]. However, there have been concerns that newer, even higher-priced basal insulin analogs are now being promoted despite their minor absolute benefits [18]. The aim of this study was to examine whether these results from randomized studies can be translated into real-world patients.

2. Materials and methods

2.1. Research design

This was a 12-month retrospective study using the record of patients from the Keio University Hospital (Tokyo, Japan). Clinical care was provided by diabetologists. The ethical guidelines for medical and health research involving human subjects were followed and the Keio University School of Medicine Ethical Committee approved the study protocol (No. 20130453).
Primary endpoint was glycated hemoglobin (HbA1c) level at month 12. Secondary endpoints were hypoglycemia for the overall study period as well as body weight and insulin dose at month 12. Data pertaining to HbA1c level, body weight, and insulin dose were extracted from the medical record. The day when the patients were switched from Gla-100 to Gla-300 was defined as day 0, and the baseline value was the nearest date when the relevant data were available within days -45 to 0. Days 90, 180, 270, and 360 were defined as the nearest date when the relevant data were available within days 45–134, 135–224, 225–314, and 315–404, respectively.

The hypoglycemic events recorded by the physician/nurse in the medical record and self-monitored blood glucose (SMBG) values recorded in the patient’s diary were included in the analysis. Events within days -90 to -1 served as the reference compared with events within days 1–90, 91–180, 181–270, and 271–360. Hypoglycemic categories included a) confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemia (severe cognitive impairment requiring external assistance for recovery), b) confirmed (<3.0 mmol/L [<54 mg/dL]) or severe hypoglycemia, and c) nocturnal hypoglycemia; confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemia between 00:00 and 05:59 h or in which the word “nocturnal” was present in the medical records. These hypoglycemic categories were chosen to be in line with the reported outcomes in the EDITION program.

2.2. Study patients

Japanese adults ≥18 years with T2DM treated with Gla-100 for ≥6 months who switched to Gla-300 during their outpatient visit between September 1, 2016 and December 31, 2016 were included. As of September 1, 2016, in-hospital prescription of Gla-100 became unavailable as a new contract with Gla-300 was implemented and virtually all patients switched from Gla-100 to Gla-300. Only six patients with T2DM switched to basal insulin other than Gla-300.

Exclusion criteria were a) change in patient’s diabetes treatment regimen except insulin dose titration or switch to combination oral antihyperglycemic drugs at similar doses, b) use of premixed insulin, c) hospitalization for education on diabetes or hospitalization for more than 28 days, d) use of glucocorticoids, or e) red blood cell transfusion within 3 months prior to and 90 days after the switch. Patients with no routine visit within four months prior to the switch or after the switch and patients not performing SMBG were also excluded. If the patients met any of the above exclusion criteria for the first time after 90 days of switch, data following that date was excluded from the analysis.

2.3. Statistical analyses

Continuous variables were analyzed using a mixed-effects model for repeated measures (MMRM) with an unstructured covariance structure. Hypoglycemic events
were analyzed using generalized estimating equations (GEE) with an unstructured correlation structure. The number of hypoglycemic events per 90 days (RR; rate ratio) was calculated using a negative binomial regression model with logarithm of the treatment period as offset, and the percent of patients experiencing ≥1 hypoglycemic event per 90 days (OR; odds ratio) was calculated using a binomial logistic regression model. A two-sided p value of less than 0.05 was considered to indicate statistical significance. All statistical analyses were performed using IBM SPSS Statistics for Windows Version 25.0 (IBM Corp., Armonk, NY, USA).

3. Results

3.1. Study patients

The study included 109 patients with T2DM. Their baseline characteristics are presented in Table 1. Records of SMBG diary were available for 81 (74.3%) patients, and among those patients, the median (interquartile range) number of SMBG per day was 1.8 (1.0–2.0).

3.2. Change in insulin dose

Mean (95% confidence interval [CI]) basal insulin dose increased from 10.5 (9.4–11.8) U/d at baseline to 10.8 (9.7–12.1) U/d at day 90 (p < 0.001), 11.1 (9.9–12.4) U/d at day 180 (p < 0.001), 11.4 (10.2–12.7) U/d at day 270 (p < 0.001), and 11.4 (10.2–12.7) U/d at day 360 (p = 0.001) (Fig. 1A). The mean (95% CI) mealtime insulin dose did not differ from the baseline of 18.9 (16.5–21.7) U/d throughout the study period (Fig. 1B).

3.3. Glycemic control

The mean (SD) HbA1c level increased from the baseline of 7.7 (1.1)% (61[12] mmol/mol) to 7.9 (1.1)% (63 [12] mmol/mol) at day 90 (p = 0.003), 7.9 (1.2)% (63 [13] mmol/mol) at day 180 (p = 0.013), and 7.9 (1.3)% (63 [14] mmol/mol) at day 270 (p = 0.042), but it did not differ significantly at day 360 with 7.7 (1.3)% (61 [14] mmol/mol) (Fig. 1C).

3.4. Confirmed (≤3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemia

Patients experienced on an average 4.99 confirmed (≤3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemic events per patient-year at baseline (Fig. 2A). It was significantly fewer at days 91–180 (RR 0.58; 95% CI 0.39–0.86; p = 0.006) but did not differ throughout the remaining study period. At baseline, 25% of the patients
Table 1. Baseline characteristics of study patients. Data are n (%), mean (standard deviation), or median (interquartile range). BMI, body mass index; DPP-IV, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HbA1c, glycated hemoglobin; SGLT2, sodium-glucose cotransporter 2.

| Characteristic                        | Value         |
|--------------------------------------|---------------|
| N                                    | 109           |
| Age (years)                          | 67.3 (12.3)   |
| Male                                 | 73 (67.0)     |
| Duration of type 2 diabetes (years)  | 23.0 (11.3)   |
| Duration of insulin use (years)      | 11.1 (8.0)    |
| Body weight (kg)                     | 69.0 (16.7)   |
| BMI (kg/m²)                           | 25.9 (5.8)    |
| Random blood glucose (mmol/L)        | 9.1 (2.9)     |
| (mg/dL)                              | 163.3 (53.0)  |
| HbA1c (%)                            | 7.7 (1.1)     |
| (mmol/mol)                           | 61 (12)       |
| Dose of basal insulin (U/d)          | 12.4 (6.0–16.5)|
| Dose of mealtime insulin (U/d)       | 22.5 (14.0–26.0)|
| Antihyperglycemic drugs              |               |
| Mealtime insulin                     | 72 (66.1)     |
| DPP-IV inhibitors                    | 63 (57.8)     |
| Biguanides                           | 30 (27.5)     |
| Glinides                             | 20 (18.3)     |
| α-glucosidase inhibitors             | 19 (17.4)     |
| SGLT2 inhibitors                     | 15 (13.8)     |
| GLP-1 receptor agonists              | 8 (7.3)       |
| Sulfonylureas                        | 7 (6.4)       |
| Thiazolidinediones                   | 7 (6.4)       |

experienced ≥1 hypoglycemic event, and there was no difference throughout the study period (Table 2A).

3.5. Confirmed (<3.0 mmol/L [< 54 mg/dL]) or severe hypoglycemia

Patients experienced an average 0.85 confirmed (<3.0 mmol/L [< 54 mg/dL]) or severe hypoglycemic events per patient-year at baseline (Fig. 2B). It was significantly fewer on days 1–90 (RR 0.45; 95% CI 0.21–0.96; p = 0.039) and days 91–180 (RR 0.49; 95% CI 0.29–0.82; p = 0.006) but was not significant on days 181–270 and 271–360. Overall, there was a 39% decrease in hypoglycemic events (RR 0.61; 95% CI 0.38–0.97; p = 0.037). At baseline, 6% of the patients experienced ≥1 hypoglycemic event, and there was no difference throughout the study period (Table 2B).
3.6. Nocturnal hypoglycemia

Patients experienced on an average 0.07 nocturnal hypoglycemic events per patient-year at baseline, and there was no difference throughout the study period (Fig. 2C). At baseline, 2% of the patients experienced ≥1 nocturnal hypoglycemic event, and there was no difference throughout the study period (Table 2C).

3.7. Body weight

The mean (SD) body weight significantly increased from the baseline of 68.9 (16.7) kg to 69.3 (16.9) kg at day 90 and decreased to 68.3 (17.1) kg at day 270, but did not differ at days 180 and 360, with 69.0 (17.1) and 68.6 (17.1) kg, respectively (Fig. 1D).

4. Discussion

In this observational retrospective study, Japanese patients with T2DM who switched to Gla-300 from Gla-100 were examined for 12 months. A significant increase in basal insulin dose was observed, but it was not associated with weight gain at day 360. The HbA1c level did not differ on day 360, but an increase was observed at days 90, 180, and 270. Seasonal fluctuations in HbA1c level are known, with the
highest HbA1c level during winter-spring and lowest during summer-autumn [19, 20]. As days 90 and 180 correspond to winter-spring, seasonal fluctuations might have accounted for the increase in HbA1c level during the study period. A decrease in annualized rates for confirmed (<3.0 mmol/L [<54 mg/dL]) or severe hypoglycemia was observed, while the percent of patients experiencing ≥1 hypoglycemic event did not differ, suggesting a benefit in patients experiencing multiple events. There was no difference in confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemia and nocturnal hypoglycemia.

A characteristic feature of the EDITION program was the reduction in nocturnal hypoglycemic events, which is in contrast with the results of our study. This
discrepancy might be in part due to the low number of nocturnal hypoglycemic events observed. For example, the number of nocturnal hypoglycemic events per patient-year in EDITION JP 2 [11] was 2.09, compared with 0.04 in our study. Several reasons might have accounted for the low number of nocturnal hypoglycemic events. First, it is difficult to detect nocturnal hypoglycemic events only from symptoms, especially in the elderly with impaired awareness of hypoglycemia [21, 22]. In a study evaluating hypoglycemia using blinded continuous glucose monitoring in elderly patients, 69% of the patients experienced at least one nocturnal hypoglycemic event, but all events were unrecognized [23]. Second, even when hypoglycemic events are recognized, patients can be reluctant to report hypoglycemic events in a real-world setting [24]. For example, in a survey of Japanese patients with diabetes, 181 patients reported of experiencing at least one nocturnal hypoglycemic event in the past 3 months, but only 33% of the patients contacted a healthcare professional after experiencing the event [25]. Third, although we excluded patients not performing SMBG, and records of SMBG diary were available for 74.3% of the patients in addition to the physician/nurse medical record, the retrospective nature is a limiting factor in the collection of data.

Another potential factor contributing to the low number of nocturnal hypoglycemic events might have been the different insulin titration strategies used. In our study, it was at the treating physician’s discretion and the mean fasting SMBG value (only a reference value as data was available for roughly 70% of the patients) was 7.8 mmol/L (139.8 mg/dL) at baseline and 8.0 mmol/L (144.2 mg/dL) on day 360. On the contrary, basal insulin dose was titrated to achieve a fasting SMBG value of 4.4–5.5 mmol/L (80–100 mg/dL) in the EDITION program with achieved mean values of 6.4–7.1 mmol/L (114.4–126.9 mg/dL) at month 6. The higher fasting SMBG value observed in our study probably reflects the fact that the study population was older with longer duration of diabetes. When targeting a more realistic fasting SMBG value

| Day       | A % of patients | B % of patients | C % of patients |
|-----------|----------------|----------------|----------------|
| -90 to -1 | 25 1.00        | 6 1.00         | 2 1.00         |
| 1–90      | 27 1.10 (0.74–1.64) | 7 1.15 (0.45–2.93) | 1 0.50 (0.04–5.63) |
| 91–180    | 25 1.01 (0.65–1.54) | 6 0.88 (0.38–2.04) | 1 0.61 (0.06–6.88) |
| 181–270   | 27 1.13 (0.70–1.81) | 5 0.78 (0.22–2.72) | 1 0.70 (0.06–7.72) |
| 271–360   | 34 1.59 (0.95–2.67) | 8 1.23 (0.49–3.06) | 2 0.84 (0.08–9.02) |

Table 2. Percent of patients experiencing ≥1 hypoglycemic event every 90 days. (A) Confirmed (≤3.9 mmol/L [≤ 70 mg/dL]) or severe hypoglycemia. (B) Confirmed (<3.0 mmol/L [< 54 mg/dL]) or severe hypoglycemia. (C) Nocturnal hypoglycemia. CI, confidence interval; OR, odds ratio.
individualized for each patient, the differences in the PK/PD profile of Gla-300 and Gla-100 might not be relevant to obtain clinical benefits. In the SENIOR study [26], which prospectively compared Gla-300 vs. Gla-100 in elderly patients (≥65 years) with T2DM, a higher fasting SMBG target of 5.0–7.2 mmol/L (90–130 mg/dL) was used, and there was no difference in the incidence and rate of hypoglycemia.

The strengths of the present study include the following. First, the risk of selection bias was very low as virtually all patients using Gla-100 switched to Gla-300. Second, we were able to follow the patients for a 12-month period, which enabled us to account for seasonal variances.

The present study had some limitations along with its observational retrospective nature. First, there was no comparison arm. Second, we were unable to capture hypoglycemic events not reported by patients as discussed above. Third, roughly 35% of the patients met the exclusion criteria before month 12, and the number of patients with measured HbA1c values was 109, 107, 97, 78, and 71 on days 0, 90, 180, 270, and 360, respectively. 31 patients had a change in their diabetes treatment regimen, 3 patients were hospitalized for education on diabetes, 2 patients were referred to a primary care clinic, 1 patient was hospitalized for more than 28 days due to septic arthritis, and 1 patient died. Fourth, mealtime insulin accounted for roughly two-thirds of the total daily insulin dose. Although basal insulin requirements in Japanese patients with type 1 diabetes has been reported to be ~30% of the total daily insulin dose, which is in contrast with Western countries where basal insulin requirements are ~50% of the total daily insulin dose [27], it was difficult to assign a hypoglycemia to basal or mealtime insulin. Finally, this study only included Japanese patients who visited a single university hospital in Tokyo where clinical care was provided by diabetologists. Therefore, the results might not be applicable to patients with diabetes in the primary care setting and other ethnic groups.

In conclusion, in Japanese patients with T2DM who switched to Gla-300 from Gla-100, similar glycemic control was achieved with fewer confirmed (<3.0 mmol/L [<54 mg/dL]) or severe hypoglycemic events during the 12-month period, although the absolute benefit was marginal. There was no difference in confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemia and nocturnal hypoglycemia.

**Declarations**

**Author contribution statement**

Kazutoshi Sugiyama: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

Shu Meguro: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper.
Yoshifumi Saisho, Junichiro Irie, Masami Tanaka, Hiroshi Itoh: Analyzed and interpreted the data.

**Funding statement**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Competing interest statement**

The authors declare the following conflict of interests:

Kazutoshi Sugiyama; no conflicts of interest.

Shu Meguro; personal fees from Takeda Pharmaceutical Co. Ltd., Japan, Nippon Boehringer Ingelheim Co. Ltd., Japan and AstraZeneca K.K., Japan outside the submitted work.

Yoshifumi Saisho; grants and personal fees from AstraZeneca K.K., Japan personal fees from Takeda Pharmaceutical Co. Ltd., Japan and Nippon Boehringer Ingelheim Co. Ltd., Japan outside the submitted work.

Junichiro Irie; personal fees from Takeda Pharmaceutical Co. Ltd., Japan outside the submitted work.

Masami Tanaka; personal fees from Novo Nordisk Pharma Ltd., Japan, Takeda Pharmaceutical Co. Ltd., Japan and Novartis Pharma Ltd., Japan outside the submitted work.

Hiroshi Itoh; grants and personal fees from Takeda Pharmaceutical Co. Ltd., Japan, Nippon Boehringer Ingelheim Co. Ltd., Japan, Daiichi Sankyo Co. Ltd., Japan, MSD K.K., Japan, Mitsubishi Tanabe Pharma Corporation, Japan, Shionogi & Co. Ltd., Japan and Taisho Toyama Pharmaceutical Co. Ltd., Japan grants from Sumitomo Dainippon Pharma Co. Ltd., Japan, Astellas Pharma Inc., Japan, Kyowa Hakko Kirin Co. Ltd., Japan, Teijin Pharma Ltd., Japan, Mochida Pharmaceutical Co. Ltd., Japan, Ono Pharmaceutical Co. Ltd., Japan, Chugai Pharmaceutical Co. Ltd., Japan, Eli Lilly Japan K.K., Japan, Sanofi K.K., Japan, Johnson & Johnson K.K., Japan and Abbott Japan Co. Ltd., Japan personal fees from Nipro Corporation, Japan, SBI Pharmaceuticals Co. Ltd., Japan outside the submitted work.

**Additional information**

No additional information is available for this paper.

**Acknowledgements**

We would like to thank Honyaku Center Inc. for English language editing.
References

[1] Y. Ohkubo, H. Kishikawa, E. Araki, T. Miyata, S. Isami, S. Motoyoshi, Y. Kojima, N. Furuyoshi, M. Shichiri, Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study, Diabetes Res. Clin. Pract. 28 (1995) 103–117.

[2] UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonlureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet (London, England) 352 (1998) 837–853.

[3] R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, H.A. Neil, 10-year follow-up of intensive glucose control in type 2 diabetes, N. Engl. J. Med. 359 (2008) 1577–1589.

[4] American Diabetes Association, 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018, Diabetes Care 41 (2018) S73–S85.

[5] International Hypoglycaemia Study Group, Minimizing hypoglycemia in diabetes, Diabetes Care 38 (2015) 1583–1591.

[6] E. Marrett, L. Radican, M.J. Davies, Q. Zhang, Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study, BMC Res. Notes 4 (2011) 251.

[7] P.E. Hypoglycaemia Cryer, The limiting factor in the glycaemic management of Type I and Type II diabetes, Diabetologia 45 (2002) 937–948.

[8] R.H. Becker, R. Dahmen, K. Bergmann, A. Lehmann, T. Jax, T. Heise, New insulin glargine 300 Units . mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units . mL-1, Diabetes Care 38 (2015) 637–643.

[9] M. Shiramoto, T. Eto, S. Irie, A. Fukuzaki, L. Teichert, J. Tillner, Y. Takahashi, M. Koyama, R. Dahmen, T. Heise, et al., Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes, Diabetes Obes. Metab. 17 (2015) 254–260.

[10] Y. Terauchi, M. Koyama, X. Cheng, Y. Takahashi, M.C. Riddle, G.B. Bolli, T. Hirose, New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral
antihyperglycaemic drugs: glucose control and hypoglycaemia in a random-
ized controlled trial (EDITION JP 2), Diabetes Obes. Metab. 18 (2016)
366—374.

[11] Y. Terauchi, M. Koyama, X. Cheng, M. Sumi, M.C. Riddle, G.B. Bolli,
T. Hirose, Glycaemic control and hypoglycaemia with insulin glargine 300
U/mL compared with glargine 100 U/mL in Japanese adults with type 2 dia-
betes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2
randomised 12-month trial including 6-month extension), Diabetes Metab. 43
(2017) 446—452.

[12] M.C. Riddle, G.B. Bolli, M. Ziemen, I. Muehlen-Bartmer, F. Bizet,
P.D. Home, New insulin glargine 300 units/mL versus glargine 100 units/
ml in people with type 2 diabetes using basal and mealtime insulin: glucose
control and hypoglycemia in a 6-month randomized controlled trial (EDITION
1), Diabetes Care 37 (2014) 2755—2762.

[13] M.C. Riddle, H. Yki-Jarvinen, G.B. Bolli, M. Ziemen, I. Muehlen-Bartmer,
S. Cissokho, P.D. Home, One-year sustained glycaemic control and less hypo-
glycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in
people with type 2 diabetes using basal plus meal-time insulin: the EDITION
1 12-month randomized trial, including 6-month extension, Diabetes Obes.
Metab. 17 (2015) 835—842.

[14] H. Yki-Jarvinen, R. Bergenstal, M. Ziemen, M. Wardecki, I. Muehlen-
Bartmer, E. Boelle, M.C. Riddle, New insulin glargine 300 units/mL versus
glargin 100 units/mL in people with type 2 diabetes using oral agents and
basal insulin: glucose control and hypoglycemia in a 6-month randomized
controlled trial (EDITION 2), Diabetes Care 37 (2014) 3235—3243.

[15] H. Yki-Jarvinen, R.M. Bergenstal, G.B. Bolli, M. Ziemen, M. Wardecki,
I. Muehlen-Bartmer, M. Maroccia, M.C. Riddle, Glycaemic control and hypo-
glycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/
ml in people with type 2 diabetes using basal insulin and oral antihyperglyca-
emic drugs: the EDITION 2 randomized 12-month trial including 6-month
extension, Diabetes Obes. Metab. 17 (2015) 1142—1149.

[16] G.B. Bolli, M.C. Riddle, R.M. Bergenstal, M. Ziemen, K. Sestakauskas,
H. Goyeau, P.D. Home, New insulin glargine 300 U/ml compared with glar-
gine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-
lowering drugs: a randomized controlled trial (EDITION 3), Diabetes Obes.
Metab. 17 (2015) 386—394.

[17] G.B. Bolli, M.C. Riddle, R.M. Bergenstal, M. Wardecki, H. Goyeau,
P.D. Home, Glycaemic control and hypoglycaemia with insulin glargine
300U/mL versus insulin glargine 100U/mL in insulin-naive people with type 2 diabetes: 12-month results from the EDITION 3 trial, Diabetes Metab. 43 (2017) 351–358.

[18] M.J. Crowley, M.L. Maciejewski, Revisiting NPH insulin for type 2 diabetes: is a step back the path forward? J. Am. Med. Assoc. 320 (2018) 38–39.

[19] H. Sakura, Y. Tanaka, Y. Iwamoto, Seasonal fluctuations of glycated hemoglobin levels in Japanese diabetic patients, Diabetes Res. Clin. Pract. 88 (2010) 65–70.

[20] K. Tanaka, S. Meguro, M. Tanaka, J. Irie, Y. Saisho, H. Itoh, Difference of seasonal variation between glycated albumin and glycated haemoglobin, Ann. Clin. Biochem. 55 (2018) 583–587.

[21] K. Matyka, M. Evans, J. Lomas, I. Cranston, I. Macdonald, S.A. Amiel, Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men, Diabetes Care 20 (1997) 135–141.

[22] J.P. Bremer, K. Jauch-Chara, M. Hallschmid, S. Schmid, B. Schultes, Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes, Diabetes Care 32 (2009) 1513–1517.

[23] M.N. Munshi, A.R. Segal, E. Suhl, E. Staum, L. Desrochers, A. Sternthal, J. Giusti, R. McCartney, Y. Lee, P. Bonsignore, et al., Frequent hypoglycemia among elderly patients with poor glycemic control, Arch. Intern. Med. 171 (2011) 362–364.

[24] R. Silbert, A. Salcido-Montenegro, R. Rodriguez-Gutierrez, A. Katabi, R.G. McCoy, Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies, Curr. Diabetes Rep. 18 (2018) 53.

[25] Y. Ohashi, M.L. Wolden, J. Hyllested-Winge, M. Brod, Diabetes management and daily functioning burden of non-severe hypoglycemia in Japanese people treated with insulin, J. Diabetes Invest. 8 (2017) 776–782.

[26] R. Ritzel, S.B. Harris, H. Baron, H. Florez, R. Roussel, M. Espinasse, I. Muehlen-Bartmer, N. Zhang, M. Bertolini, C. Brulle-Wohlhueter, et al., A randomized controlled trial comparing efficacy and safety of insulin glargine 300 Units/mL versus 100 Units/mL in older people with type 2 diabetes: results from the SENIOR study, Diabetes Care 41 (2018) 1672–1680.

[27] A. Kuroda, H. Kaneto, T. Yasuda, M. Matsuhisa, K. Miyashita, N. Fujiki, K. Fujisawa, T. Yamamoto, M. Takahara, F. Sakamoto, et al., Basal insulin requirement is ~30% of the total daily insulin dose in type 1 diabetic patients who use the insulin pump, Diabetes Care 34 (2011) 1089–1090.